Topical Diclofenac and Vitamin D3 to treat Basal Cell Carcinoma - VitaDi
- Conditions
- Basal Cell Carcinoma
- Registration Number
- EUCTR2010-022410-11-NL
- Lead Sponsor
- MUMC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 64
Minimum age 18 years
Primary basal cell carcinoma, histologically confirmed
Nodular of micronodular histological subtype
Comorbidities may not interfere with study treatment
Capable to understand instructions
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Age under 18 years
Tumors located at the H-zone of the face
Deficient histological conformation
Proven or suspected malignancy of other organs
Not capable of comprehending instructions
Incompetent
Use of oral NSAIDs during the trial period or within 30 days before starting therapy
Use of oral vitamin D (containing) supplements during the trial period or within 30 days before starting therapy
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method